How Does Brexpiprazole Work?

Brexpiprazole, commonly known by the brand name Rexulti, is an atypical antipsychotic medication used to treat schizophrenia and, at lower doses, as an add-on treatment for major depressive disorder when an antidepressant alone has not provided enough benefit. It is also approved for certain patients with agitation associated with Alzheimer’s dementia.

Brexpiprazole works mainly by modifying two important neurotransmitter systems in the brain:

• Dopamine
• Serotonin Unlike traditional antipsychotics that primarily block dopamine receptors, brexpiprazole acts as a partial agonist at dopamine D2 receptors. This means that it activates the receptor, but less strongly than dopamine itself.

Brexpiprazole also acts as a:

• Dopamine D3 partial agonist
• Serotonin 5-HT1A partial agonist
• Serotonin 5-HT2A antagonist These combined effects modify signaling in brain circuits involved in mood, motivation, perception, cognition and behaviour. The precise mechanism responsible for brexpiprazole’s clinical effects is not completely understood.

How Does Brexpiprazole Affect Dopamine?

Dopamine plays an important role in:

• Motivation
• Reward
• Pleasure
• Attention
• Movement
• Thinking
• Perception
• Behaviour Brexpiprazole interacts strongly with the dopamine D2 receptor.

It is a partial D2 agonist, meaning it produces some receptor activity but less than dopamine itself.

This creates an important difference from traditional dopamine-blocking antipsychotics.

When dopamine activity is excessive

If a large amount of dopamine is stimulating D2 receptors:

1. High dopamine activity
2. Brexpiprazole competes with dopamine for D2 receptors
3. Brexpiprazole produces weaker receptor activation than dopamine
4. Excessive dopamine signaling may be reduced

When dopamine activity is lower

Brexpiprazole can still activate D2 receptors to some degree:

1. Lower dopamine activity
2. Brexpiprazole provides partial D2 stimulation
3. Some dopamine signaling is maintained

This is why brexpiprazole is sometimes described as a dopamine modulator rather than simply a dopamine blocker.

That description is useful for understanding the medication, although the actual response depends on the brain region, dopamine concentration, receptor occupancy and downstream signaling.

How Does Brexpiprazole Work for Schizophrenia?

Schizophrenia can involve abnormalities in several neurotransmitter pathways, but dopamine signaling is particularly important.

Excessive dopamine signaling through D2 receptors in certain brain pathways, particularly the mesolimbic pathway, is associated with positive psychotic symptoms such as:

• Hallucinations
• Delusions
• Paranoia
• Disorganized thinking Brexpiprazole can occupy D2 receptors while stimulating them less strongly than dopamine.

The simplified pathway is:

1. Excessive dopamine signaling
2. Brexpiprazole occupies D2 receptors
3. D2 signaling is moderated
4. Activity in psychosis-related brain circuits changes
5. Hallucinations, delusions and other symptoms may improve

Brexpiprazole’s serotonin effects may also influence dopamine signaling in other brain regions and contribute to its overall antipsychotic action.

How Does Brexpiprazole Work for Depression?

Brexpiprazole is also used as an adjunctive treatment for major depressive disorder.

Adjunctive means that it is added to an antidepressant when the antidepressant alone has not produced enough improvement.

Depression can involve multiple neurotransmitter systems, including:

• Serotonin
• Dopamine
• Norepinephrine An antidepressant may increase neurotransmitter availability, but that does not necessarily mean the downstream receptors and brain circuits respond optimally.

Brexpiprazole takes a different approach.

Instead of primarily increasing the amount of serotonin or dopamine, it directly modifies several receptors:

• D2/D3 partial agonism
• 5-HT1A partial agonism
• 5-HT2A antagonism

1. Dopamine and serotonin signaling changes
2. Mood, motivation and emotional-regulation circuits may respond differently
3. Depressive symptoms may improve

This helps explain why adding brexpiprazole can sometimes provide additional benefit when an antidepressant alone has produced only a partial response.

Why Might Brexpiprazole Help When an Antidepressant Alone Does Not?

Antidepressants and brexpiprazole affect the brain in different ways.

For example, an SSRI primarily:

1. Blocks the serotonin transporter
2. Increases serotonin availability

Brexpiprazole acts further downstream at several receptors:

• 5-HT1A
• 5-HT2A
• D2/D3 Modifies serotonin-dopamine signaling Therefore, the combination can influence more than simply the amount of serotonin between nerve cells.

This is one reason augmentation with brexpiprazole may be considered when depressive symptoms such as the following remain despite antidepressant treatment:

• Low mood
• Loss of interest
• Reduced motivation
• Low emotional engagement
• Cognitive symptoms
• Incomplete overall response It does not mean that these symptoms are caused by one specific neurotransmitter deficiency. Depression involves multiple interacting biological systems.

What Does Brexpiprazole Do to Serotonin?

Brexpiprazole is not an SSRI.

It does not primarily work by preventing serotonin reuptake.

Instead, it acts directly on several serotonin receptors.

Two are particularly important.

• 5-HT1A Receptor Brexpiprazole is a 5-HT1A partial agonist

The 5-HT1A receptor is involved in:

• Mood

• Anxiety

• Stress regulation

• Emotional processing

• Serotonin feedback

• Dopamine-serotonin interactions Partial activation of this receptor may contribute to brexpiprazole’s effects on mood and emotional regulation.

• 5-HT2A Receptor Brexpiprazole is a: 5-HT2A antagonist

This means that when brexpiprazole occupies the receptor, it prevents serotonin from fully activating it.

5-HT2A receptors influence:

• Perception
• Cognition
• Mood
• Arousal
• Sleep
• Dopamine release in several brain pathways Antagonism of 5-HT2A receptors is a common feature of many atypical antipsychotic medications.

What Does Brexpiprazole Do to Dopamine D3 Receptors?

Brexpiprazole also has high affinity for the dopamine D3 receptor and acts as a partial agonist.

D3 receptors are concentrated in areas of the brain involved in:

• Motivation
• Reward
• Emotion
• Cognition
• Behaviour D3 activity may therefore contribute to some of brexpiprazole’s effects beyond control of psychotic symptoms.

However, the exact clinical contribution of D3 receptor activity is not as firmly established as the overall D2/5-HT1A/5-HT2A mechanism.

Does Brexpiprazole Affect Other Receptors?

Yes. Brexpiprazole interacts with several additional serotonin and adrenergic receptors.

Current pharmacological data show antagonist activity at receptors including:

• 5-HT7
• 5-HT2B
• α1A-adrenergic
• α1B-adrenergic
• α1D-adrenergic
• α2C-adrenergic It also has considerably weaker affinity for histamine H1 receptors than for its principal dopamine and serotonin targets.

These additional interactions may contribute to differences in:

• Alertness
• Blood pressure
• Cognition
• Mood
• Side-effect profile However, their exact contribution to clinical effectiveness is not fully established.

Why Can Brexpiprazole Cause Akathisia or Restlessness?

One of the more recognizable side effects of brexpiprazole is akathisia.

Akathisia is an uncomfortable internal restlessness that can cause:

• An urge to move
• Difficulty sitting still
• Pacing
• Constant leg movement
• Physical agitation Because brexpiprazole occupies dopamine D2 receptors and changes dopamine signaling, it can influence pathways involved in movement and behavioural activation.

For some people, this produces therapeutic effects.

For others, particularly when exposure or receptor occupancy becomes too high, it may contribute to restlessness or akathisia.

Akathisia can sometimes be mistaken for anxiety or worsening psychiatric symptoms, so recognizing its relationship to medication can be important.

Why Can the Same Dose of Brexpiprazole Affect Two People Differently?

Two people can take the same dose of brexpiprazole and experience very different results.

One person may have:

• Good symptom control

• Few side effects Another may experience:

• Akathisia

• Sleepiness

• Restlessness

• Weight gain

• Dizziness

• Tremor A third person may experience inadequate benefit.

One important reason is that people do not all metabolize brexpiprazole at the same rate.

Two liver enzymes are particularly important:

CYP2D6 and CYP3A4

Brexpiprazole is primarily metabolized through these pathways. Its major circulating metabolite, DM-3411, is not considered to contribute meaningfully to its therapeutic effects.

How Is Brexpiprazole Metabolized?

A simplified pathway is:

1. Brexpiprazole is taken
2. Absorbed into the bloodstream
3. CYP2D6 + CYP3A4 metabolize brexpiprazole
4. Drug is gradually cleared from the body

The parent medication itself is responsible for the principal therapeutic activity.

Brexpiprazole also has a relatively long elimination half-life of approximately 91 hours, meaning it remains in the body for several days.

How Does CYP2D6 Affect Brexpiprazole?

The CYP2D6 gene contains the instructions used to make the CYP2D6 enzyme.

Different people inherit different CYP2D6 variants.

As a result, they may have:

• Poor CYP2D6 activity
• Intermediate CYP2D6 activity
• Normal CYP2D6 activity
• Ultrarapid CYP2D6 activity The most clinically established relationship for brexpiprazole involves:

CYP2D6 Poor Metabolizers

These individuals have little or no functioning CYP2D6 enzyme.

Therefore:

1. Low CYP2D6 activity
2. Brexpiprazole metabolism decreases
3. Brexpiprazole remains in the body longer
4. Drug exposure increases
5. Potentially greater risk of concentration-related adverse effects

This relationship is sufficiently established that the FDA identifies brexpiprazole–CYP2D6 as a pharmacogenetic association for which dosage adjustment is recommended in Poor Metabolizers.

Can Other Medications Change Brexpiprazole Metabolism?

Yes. Someone may genetically have normal CYP2D6 activity but take another medication that inhibits the enzyme.

Important CYP2D6 inhibitors include:

• Fluoxetine
• Paroxetine
• Bupropion For example:

CYP2D6 Normal Metabolizer

• Strong CYP2D6 inhibitor

1. CYP2D6 function decreases
2. Brexpiprazole metabolism slows
3. Brexpiprazole exposure may increase

This is an example of phenoconversion.

The person’s genes have not changed, but their actual enzyme function changes because of another medication.

What Is the Role of CYP3A4?

CYP3A4 is the other major enzyme responsible for brexpiprazole metabolism.

Certain medications strongly inhibit CYP3A4.

Examples include:

• Clarithromycin
• Ketoconazole
• Itraconazole These can:

1. Reduce CYP3A4 metabolism
2. Increase brexpiprazole exposure

Other medications, particularly carbamazepine and rifampin, can strongly increase CYP3A4 activity.

This can result in:

1. More rapid metabolism
2. Lower brexpiprazole concentrations
3. Potentially reduced therapeutic effect

This is why genetics and medication interactions need to be considered together.

Can Brexpiprazole Fail Even If You Metabolize It Normally?

Yes. Normal metabolism does not guarantee that brexpiprazole will work.

There are two major parts to medication response.

Pharmacokinetics: How Your Body Handles Brexpiprazole

Pharmacokinetics, or PK, describes what the body does to the medication.

This includes:

• Absorption
• Distribution
• Metabolism
• Elimination For brexpiprazole, two particularly important metabolic pathways are: CYP2D6 + CYP3A4

The goal is ultimately to achieve an appropriate concentration of brexpiprazole in the body and brain. But getting the right amount of medication to the brain is only the first step.

Pharmacodynamics: How Your Brain Responds to Brexpiprazole

Pharmacodynamics, or PD, describes what the medication does after it reaches its biological targets. Brexpiprazole interacts with several important receptors.

DRD2 — Dopamine D2 Receptor

D2 is one of brexpiprazole’s principal targets.

Brexpiprazole acts as a partial agonist at this receptor.

D2 signaling is important for:

• Psychosis
• Motivation
• Reward
• Behaviour
• Movement

DRD3 — Dopamine D3 Receptor

Brexpiprazole also acts as a partial agonist at D3 receptors.

D3 signaling is particularly associated with:

• Motivation
• Reward
• Emotional processing
• Cognition

HTR1A — Serotonin 5-HT1A Receptor

Brexpiprazole acts as a partial agonist at the 5-HT1A receptor.

This receptor influences:

• Mood
• Anxiety
• Stress regulation
• Serotonin signaling
• Dopamine-serotonin interactions

HTR2A — Serotonin 5-HT2A Receptor

Brexpiprazole acts as an antagonist at the 5-HT2A receptor.

5-HT2A signaling influences:

• Perception
• Mood
• Cognition
• Arousal
• Dopamine release The D2, D3, 5-HT1A and 5-HT2A receptor profile forms a major part of brexpiprazole’s pharmacodynamic activity.

Brexpiprazole Needs Both Drug Exposure and Brain Response

A simplified way of understanding brexpiprazole response is:

1. Brexpiprazole is taken
2. The body absorbs and metabolizes the medication — PK
3. CYP2D6 + CYP3A4
4. An appropriate amount of brexpiprazole reaches the brain
5. Brexpiprazole interacts with dopamine and serotonin receptors — PD
6. D2/D3 + 5-HT1A + 5-HT2A
7. Dopamine and serotonin signaling changes
8. Relevant brain circuits respond
9. Symptoms may improve

This helps explain an important concept:

Normal PK does not automatically mean optimal PD response.

A person may metabolize brexpiprazole normally but still experience limited benefit if the relevant dopamine and serotonin pathways do not respond in the way needed for that individual’s symptoms.

Why Can Too Much or Too Little Dopamine Signaling Be a Problem?

Dopamine should not simply be thought of as either “high” or “low” throughout the entire brain.

Different dopamine pathways perform different functions.

Excessive dopamine signaling in certain pathways

may contribute to:

• Hallucinations
• Delusions
• Paranoia
• Agitation

Insufficient dopamine signaling in other pathways

may contribute to:

• Low motivation
• Reduced pleasure
• Cognitive difficulties
• Reduced emotional engagement Brexpiprazole’s partial D2 agonist action is therefore different from simply attempting to:

“Block dopamine.”

A better simplified description is:

Brexpiprazole modifies dopamine receptor signaling.

The effect depends partly on the amount of dopamine activity already present, and the brain pathway involved.

How Is Brexpiprazole Different from Aripiprazole?

Brexpiprazole and aripiprazole are closely related atypical antipsychotics.

Both act as:

• D2 partial agonists
• 5-HT1A partial agonists
• 5-HT2A antagonists However, their receptor-binding profiles and intrinsic activity are not identical.

Brexpiprazole was designed with a somewhat different balance of dopamine, serotonin and adrenergic receptor activity.

As a result, the two medications should not be considered interchangeable even though their broad mechanisms are similar.

A person may respond differently to brexpiprazole than to aripiprazole in terms of both:

• Therapeutic benefit
• Side effects

Does a Genetic Test Tell You Whether Brexpiprazole Will Work?

No genetic test can currently guarantee whether brexpiprazole will work for a particular person.

Medication response depends on many factors, including:

• Genetics
• Diagnosis
• Symptoms
• Dose
• CYP2D6 activity
• CYP3A4 drug interactions
• Other medications
• Dopamine signaling
• Serotonin signaling
• Receptor biology
• Previous treatment response
• Side-effect sensitivity
• Individual brain biology A genetic result should therefore be considered as one component of personalized medication selection rather than a stand-alone answer.

Can Pharmacogenomic Testing Help with Brexpiprazole Response?

Yes, particularly for understanding brexpiprazole metabolism and drug exposure.

The most clinically established pharmacogenomic gene for brexpiprazole is: CYP2D6

The FDA specifically recognizes the CYP2D6–brexpiprazole relationship and notes that CYP2D6 Poor Metabolizers have higher systemic drug concentrations and require dosage adjustment according to the prescribing information.

A pharmacogenomic test can help identify whether a person is predicted to have:

• Poor
• Intermediate
• Normal
• Ultrarapid CYP2D6 activity.

For a CYP2D6 Poor Metabolizer:

1. Slower brexpiprazole metabolism
2. Higher drug exposure
3. Dose adjustment may be appropriate

The result should also be interpreted together with medications that inhibit CYP2D6 or CYP3A4.

Can Pharmacodynamic Genes Affect Brexpiprazole Response?

Brexpiprazole acts on proteins encoded by several genes, including:

• DRD2 — dopamine D2 receptor
• DRD3 — dopamine D3 receptor
• HTR1A — serotonin 5-HT1A receptor
• HTR2A — serotonin 5-HT2A receptor Genetic variation in dopamine and serotonin pathways has been investigated as a possible contributor to differences in antipsychotic response and adverse effects.

However: These pharmacodynamic genes do not currently have established genotype-based brexpiprazole dosing guidelines. Their interpretation is therefore more complex than the established CYP2D6 pharmacokinetic relationship.